Deutscher Platz 5a
Leipzig 04103
Germany
49 341 48792 40
https://www.vita34.de
Settore/i:
Settore:
Impiegati a tempo pieno: 745
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Jakub Julian Baran | Chairman of the Management Board & CEO | N/D | N/D | N/D |
Mr. Tomasz Franciszek Baran | Vice President of the Management Board & Chief Commercial Officer | N/D | N/D | N/D |
Thomas Pfaadt | Chief Financial Officer | N/D | N/D | N/D |
Santiago Luengo | Managing Director of Secuvita | N/D | N/D | N/D |
VITA 34 AG engages in the collection, processing, cryopreservation, and storage of stem cells from umbilical cord blood and tissue and postnatal tissue in Germany, Poland, Portugal, and internationally. It operates through Subgroup Vita 34 And Subgroup PBKM segments. The company produces and develops advanced therapies, genetic tests, and analyses for third parties. It also develops products and drugs based on cells, tissues, and blood for medical applications; and produces and manufactures viral vectors and CAR-T cells. In addition, the company provides biobanking services, such as freezing sperm and storage of adipose tissue and the isolation of cells from the stored materials. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
L'ISS Governance QualityScore di VITA 34 AG al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.